16 July 2021
A Powerful Workflow to Access Cancer Gene Expression Signatures
In additional to DNA sequencing, RNA sequencing can provide researchers and clinicians with additional insights into tumor tissues. The technology offers the opportunity to explore the gene expression profiles and the states of tumor cells in real time.
16 July 2021
Slight revenue growth despite the impact of the pandemic during the first half of the year. Strong increase in order intake sets the stage for an anticipated dynamic growth during the second half of the 2021.
EVRY, FRANCE, FRIDAY 16 JULY 2021, 7.30AM – IntegraGen (FR0010908723 – ALINT (…) »
25 June 2021
Founded in 1961, the Antoine Lacassagne Center is one of the 18 French Cancer Centers of the Unicancer network. It fulfills missions of care, research and teaching in oncology. The Antoine Lacassagne Center treats all types of cancer and receives more than 6,400 patients (…) »
16 June 2021
Following its acquisition by OncoDNA, IntegraGen has been given a brand new look and is ready to take on new projects in the fields of cancer and genetic diseases.
Since the successful takeover in November 2020, IntegraGen has been working hand in hand with OncoDNA (…) »
15 March 2021
Uropathogenic E.coli induces DNA damage in the bladder
As provider of the whole genome sequencing, IntegraGen is proud of sharing this new publication.
Urinary tract infections (UTIs) are caused by an uropathogenic strain of Escherichia coli that produce colibactin, a bacterial genotoxin.
In the study (…) »
03 March 2021
Myogenesis modelled by human pluripotent stem cells: a multi-omic study of Duchenne myopathy early onset
As provider of the bulk and single-cell RNA-seq libraries and sequencing, IntegraGen is proud of sharing this new publication.
Duchenne Muscular Dystrophy (DMD) is a rare disease characterized by early muscular damages. The (…) »
12 January 2021
IntegraGen announced today its unaudited business figures for the year 2020.
2020 revenue amounted to 9.0 M € versus 8.1 M € in 2019, an increase of 10% over 12 months. Increased sequencing services reported for company’s Evry lab and at outsourced platforms run by the company for the SeqOIA (…) »
09 October 2020
LP-WGS analysis of liquid biopsies (ctDNA) for oncology applications Background
Analysis of circulating tumor DNA (ctDNA) offers great opportunities for cancer research and patient care. There are multiple applications and benefits associated with studying ctDNA including the ability to identify tumor heterogeneity and the detection of somatic mutations unidentified following (…) »
18 September 2020
IntegraGen has announced today its financial results for the first half of 2020 with the accounts having been reviewed by the Board of Directors on 17 September 2020.
Company posts positive operating performance (EBITDA) for the second consecutive semester, supported by revenue growth (+5%) and confirms (…) »
16 September 2020
This press release was prepared and distributed by OncoDNA S.A. in accordance with the provisions of Articles 231-27 1 ° and 2 ° and 231-28 of the general regulations of the Autorité des marchés financiers (the “AMF”).